Thyroid Cancer
Specialty Channel

Featured Article
Researchers found that artificial light at night may disrupt circadian rhythm, leading to an increased risk of developing thyroid cancer.
Researchers have found a significant increase in the OS of patients with ATC patients from 2000 to 2019, suggesting that advances in treatment have improved survival.
True or false: A phase 1/2 trial found Selpercatinib to be ineffective in patients with RET-mutant medullary thyroid cancer.
Selpercatinib was shown to be effective, with manageable safety, in patients with RET+ medullary thyroid cancer in a phase 1/2 trial.
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
The FDA recently approved pralsetinib for RET-altered _______ thyroid cancer.
The FDA has approved pralsetinib for the treatment of adult and pediatric patients with RET-mutated thyroid cancer.
Study findings suggest there may be an association between advancing age and reduced risk for papillary thyroid tumor enlargement being actively monitored.
The FDA has approved selpercatinib for the treatment of patients with NSCLC, MTC, and other thyroid cancers with tumors harboring a RET alteration.

News

Researchers found that artificial light at night may disrupt circadian rhythm, leading to an increased risk of developing thyroid cancer.
Researchers have found a significant increase in the OS of patients with ATC patients from 2000 to 2019, suggesting that advances in treatment have improved survival.
Selpercatinib was shown to be effective, with manageable safety, in patients with RET+ medullary thyroid cancer in a phase 1/2 trial.
The FDA has approved pralsetinib for the treatment of adult and pediatric patients with RET-mutated thyroid cancer.

Interactive Features

True or false: A phase 1/2 trial found Selpercatinib to be ineffective in patients with RET-mutant medullary thyroid cancer.
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
The FDA recently approved pralsetinib for RET-altered _______ thyroid cancer.
Stay in the know.
OncNet Newsletter